The author reflects on the transition considerations for extended half-life (EHL) factor and two recombinant factor IX (FIX) products. Topics discussed include the relationship of package insert to the real-life practice of drug prescription, the possibility of the existence of patients who have two products at home for different indications, and the approach to transitioning to EHL products.